Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Sold by Comerica Bank
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Sold by Comerica Bank
Comerica Bank trimmed its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating) by 22.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 98,127 shares of the biotechnology company's stock after selling 27,845 shares during the period. Comerica Bank's holdings in Ironwood Pharmaceuticals were worth $1,031,000 at the end of the most recent quarter.
根据最近提交给美国证券交易委员会的13F文件,Comerica银行在第三季度减持了铁木制药公司(纳斯达克:IRWD-GET评级)的股票22.1%。该公司在此期间出售了27,845股后,持有这家生物技术公司的98,127股票。截至最近一个季度末,Comerica银行持有的Ironwood PharmPharmticals股份价值1,031,000美元。
Other large investors have also made changes to their positions in the company. Raymond James & Associates lifted its position in Ironwood Pharmaceuticals by 11.1% during the first quarter. Raymond James & Associates now owns 24,117 shares of the biotechnology company's stock valued at $303,000 after purchasing an additional 2,418 shares during the period. Cetera Advisor Networks LLC raised its stake in shares of Ironwood Pharmaceuticals by 8.8% during the 1st quarter. Cetera Advisor Networks LLC now owns 11,021 shares of the biotechnology company's stock valued at $139,000 after buying an additional 893 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Ironwood Pharmaceuticals by 6.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 41,253 shares of the biotechnology company's stock valued at $518,000 after buying an additional 2,402 shares during the period. MetLife Investment Management LLC boosted its stake in shares of Ironwood Pharmaceuticals by 55.5% in the first quarter. MetLife Investment Management LLC now owns 79,249 shares of the biotechnology company's stock worth $997,000 after buying an additional 28,288 shares during the last quarter. Finally, Rhumbline Advisers grew its holdings in Ironwood Pharmaceuticals by 4.0% during the first quarter. Rhumbline Advisers now owns 164,608 shares of the biotechnology company's stock worth $2,071,000 after acquiring an additional 6,277 shares during the period.
其他大型投资者也改变了他们在该公司的头寸。Raymond James&Associates在第一季度将其在Ironwood PharmPharmticals的头寸提高了11.1%。Raymond James&Associates在此期间又购买了2,418股,现在拥有24,117股这家生物技术公司的股票,价值30.3万美元。Eltera Advisor Networks LLC在第一季度将其在Ironwood PharmPharmticals的股份增加了8.8%。Eltera Advisor Networks LLC现在拥有这家生物技术公司11,021股股票,价值13.9万美元,上个季度又购买了893股。PNC金融服务集团在第一季度增持了6.2%的Ironwood PharmPharmticals股票。PNC金融服务集团(PNC Financial Services Group Inc.)现在持有这家生物技术公司41,253股股票,价值518,000美元,在此期间又购买了2,402股。大都会人寿投资管理有限责任公司在第一季度增持了55.5%的Ironwood PharmPharmticals股票。大都会人寿投资管理公司现在拥有79,249股这家生物技术公司的股票,价值99.7万美元,在上个季度又购买了28,288股。最后,Rhumbline Advisers在第一季度增持了4.0%的Ironwood PharmPharmticals股份。在此期间,Rhumbline Advisers又收购了6,277股,现在拥有164,608股这家生物技术公司的股票,价值2,071,000美元。
Ironwood Pharmaceuticals Stock Up 0.6 %
铁木制药类股上涨0.6%
IRWD opened at $11.46 on Wednesday. The company has a fifty day moving average of $11.88 and a two-hundred day moving average of $11.37. The stock has a market capitalization of $1.76 billion, a price-to-earnings ratio of 12.06 and a beta of 0.96. Ironwood Pharmaceuticals, Inc. has a fifty-two week low of $9.73 and a fifty-two week high of $12.95. The company has a debt-to-equity ratio of 0.67, a quick ratio of 25.78 and a current ratio of 25.78.
IRWD周三开盘报11.46美元。该公司的50日移动均线切入位在11.88美元,200日移动均线切入位在11.37美元。该股市值为17.6亿美元,市盈率为12.06倍,贝塔系数为0.96。Ironwood PharmPharmticals,Inc.股价为52周低点9.73美元,52周高点12.95美元。该公司的负债权益比率为0.67,速动比率为25.78,流动比率为25.78。
Insider Activity
内幕活动
In other news, CEO Thomas A. Mccourt sold 110,962 shares of the stock in a transaction that occurred on Thursday, January 5th. The stock was sold at an average price of $12.07, for a total transaction of $1,339,311.34. Following the transaction, the chief executive officer now owns 712,440 shares in the company, valued at approximately $8,599,150.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 13.10% of the company's stock.
在其他消息方面,首席执行官托马斯·A·麦考特在1月5日星期四的一笔交易中出售了110,962股该公司股票。该股以12.07美元的平均价格出售,总成交金额为1,339,311.34美元。交易完成后,这位首席执行官现在拥有该公司712,440股票,价值约8,599,150.80美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可在这个环节。公司内部人士持有该公司13.10%的股份。
Analysts Set New Price Targets
分析师设定新的价格目标
Separately, StockNews.com downgraded Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday, December 17th.
另外,StockNews.com在12月17日(星期六)的一份报告中将Ironwood PharmPharmticals的评级从“强力买入”下调至“买入”。
About Ironwood Pharmaceuticals
铁木制药公司简介
(Get Rating)
(获取评级)
Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.
Ironwood PharmPharmticals,Inc.是一家保健公司,专注于胃肠(GI)产品的开发和商业化。它在美国和墨西哥以Linzess的名义销售利纳克肽,在加拿大和欧盟以Constella的名义销售利纳克肽,这是一种鸟苷环化酶C型激动剂,用于治疗患有便秘(IBS-C)或慢性特发性便秘(CIC)的成年人。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Ironwood Pharmaceuticals (IRWD)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab's First U.S. Launch Send Stock Into Stratosphere?
- Is It Time To Get Aggressive With Defense Stocks?
- 免费获取StockNews.com关于铁木制药的研究报告(IRWD)
- 柔顺治疗公司的差距增加了34%:未来还会有更多的好处吗?
- 2023年初裁员将如何影响这5只生物科技股?
- Baudax Bio投资者在经历了70%的飙升后,痛苦是否已经结束?
- 火箭实验室的首次美国发射将把斯托克送入平流层吗?
- 现在是时候积极投资国防类股了吗?
Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating).
想看看其他对冲基金持有IRWD的股票吗?访问HoldingsChannel.com获取铁木制药公司(纳斯达克代码:IRWD-GET Rating)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受Ironwood PharmPharmticals Daily新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Ironwood PharmPharmticals和相关公司的最新新闻和分析师评级的每日简要摘要。